LigIT raises nearly 50 million yuan seed round for AI peptide design
The Chinese startup says its platform runs a 72-hour design-to-synthesis loop for linear and cyclic peptides against tumor and metabolic targets.
TR
By Tom Reyes · Markets Editor
Oct 10 00:25 ETSource: eu.36kr.com
The wire
- 01LigIT (LiTai Intelligent Pharma) closed a seed round of nearly 50 million yuan led by iFlytek Venture Capital and the L2F Lighthouse Founders' Fund, with Lighthouse Capital as financial advisor.
- 02The company targets cyclic peptide drug design, citing scarce public structural data and poor in vivo stability of natural peptides as the bottlenecks it aims to address.
- 03The company says its platform has been validated on several tumor and metabolism targets; no clinical candidates or external data have been disclosed.
From the source
Read at eu.36kr.comLitai Intelligent Pharma Secures Nearly 50 Million Yuan in Seed Round Financing to Build a Leading AI-Native Peptide Drug R&D Platform
AI-native polypeptide drug R&D enterprise LigIT (LiTai Intelligent Pharma) announces the completion of a seed round financing of nearly 50 million yuan . This round is jointly invested by iFlytek Venture Capital, L2F Lighthouse Founders' Fund and well-known industrial partners , with Lighthouse Capital acting as the exclusive financial advisor . The funds will be mainly used for core pipeline R&D,
Source URL https://eu.36kr.com/en/p/4019481828628101
